What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Stock analysts at Lifesci Capital upped their FY2025 EPS estimates for Enliven Therapeutics in a research note issued on Wednesday, November 12th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($1.80) per share for the year, up from their prior estimate of ($1.96). The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share. Lifesci Capital also issued estimates for Enliven Therapeutics’ Q4 2025 earnings at ($0.45) EPS.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11.

Several other equities research analysts also recently commented on ELVN. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.20.

Enliven Therapeutics Trading Up 8.9%

Shares of ELVN stock opened at $22.07 on Monday. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -11.99 and a beta of 0.79. The business’s 50-day moving average price is $20.23 and its 200-day moving average price is $20.09. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $26.48.

Insider Activity

In other news, CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $21.33, for a total transaction of $266,625.00. Following the completion of the sale, the chief executive officer owned 902,892 shares of the company’s stock, valued at $19,258,686.36. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $20.24, for a total transaction of $134,940.08. Following the completion of the transaction, the chief operating officer directly owned 283,308 shares in the company, valued at approximately $5,734,153.92. This represents a 2.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 89,591 shares of company stock worth $1,813,681 over the last quarter. 25.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently bought and sold shares of ELVN. TCG Crossover Management LLC purchased a new position in Enliven Therapeutics in the 2nd quarter worth approximately $9,990,000. Duquesne Family Office LLC lifted its position in Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after buying an additional 484,405 shares in the last quarter. Candriam S.C.A. acquired a new position in Enliven Therapeutics during the second quarter worth $8,358,000. Franklin Resources Inc. grew its holdings in Enliven Therapeutics by 2,029.3% in the 2nd quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after buying an additional 410,034 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter worth $8,024,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.